Hong Kong Stock Movement: Innovative Drug Approval Boosts XUANZHUBIO-B by 22.75%, Market Confidence Significantly Increases

Hong Kong Stock Movement

XUANZHUBIO-B surged 22.75%. According to recent important news:

1. On October 21, XUANZHUBIO-B performed strongly in the Hong Kong stock market, with its stock price rising over 234% compared to the IPO price. The company was spun off from Sihuan Pharmaceutical and possesses multiple drug assets, with its commercialization strategy gaining market recognition, driving the stock price up. Data source: Zhitong Finance APP.

2. On October 20, XUANZHUBIO-B presented the Phase III clinical analysis results of pyrotinib combined with letrozole or anastrozole at the European Society for Medical Oncology, showing significant efficacy advantages, reducing the risk of disease progression and boosting market confidence. Data source: Zhitong Finance APP.

3. On October 22, pyrotinib tablets, as a new CDK2/4/6 inhibitor, were approved by the National Medical Products Administration of China, further consolidating the company's position in the innovative drug field and stimulating the stock price increase. Data source: Zhitong Finance APP. The innovative drug sector in the Hong Kong stock market is performing actively, with significant capital inflow.

Stocks with High Trading Volume in the Industry

Shijiazhuang Pharmaceutical Group fell 2.91%. According to recent important news:

1. On October 20, Shijiazhuang Pharmaceutical Group's JSKN003, developed in collaboration with CanSino Biologics, received breakthrough therapy designation from the National Medical Products Administration for the treatment of HER2-positive advanced colorectal cancer patients. This news caused stock price fluctuations as the market is full of expectations for the drug's potential;

2. On October 20, shareholder equity disclosure showed that Cai Dongchen's shareholding ratio slightly increased, and the market is paying attention to changes in the company's governance structure;

3. On October 20, preliminary research results indicated that JSKN003 has significant efficacy and good safety in treating HER2 high-expressing advanced colorectal cancer patients, further enhancing market confidence in the drug. The chemical pharmaceutical industry has been active recently, with significant capital inflow.

China Biologic Products fell 1.76%. According to recent important news:

1. On October 21, China Biologic Products announced the Phase III clinical research results of cumocycline capsules for HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology, showing positive efficacy and safety. This news failed to boost the stock price and instead led to a decline due to market concerns about future profitability. Data source: Zhitong Finance.

2. On October 19, research results showed that cumocycline made breakthrough progress in the treatment of HR+/HER2- breast cancer; however, the market remains cautious about the speed of its commercialization process and competitive pressures, affecting investor confidence. Data source: Citeline.

3. On October 21, investment banks rated China Biologic Products as a buy, but the target price was below current market expectations, leading to fluctuations in investor sentiment. Data source: CMB International. The chemical pharmaceutical industry is volatile, with attention on policy changes Hengrui Medicine fell 0.70%. According to recent key news:

4. On October 22, the total IPO fundraising in the Hong Kong stock market exceeded HKD 190 billion, with leading A-share companies like Hengrui Medicine successively landing on the Hong Kong Stock Exchange, becoming a main force in the A+H listing boom. This move enhanced the liquidity and asset quality of the Hong Kong stock market but also brought short-term volatility. Data source: People's Financial News

5. On October 20, the National Medical Products Administration approved metformin and empagliflozin tablets from multiple companies, intensifying competition. This move may affect Hengrui Medicine's market share, leading to a decline in stock price. Data source: National Medical Products Administration official website

6. On October 19, Hengrui Medicine's oncology department achieved a significant breakthrough in breast cancer treatment, with a median overall survival of 35.81 months among participants. Although this news is favorable for long-term development, it failed to boost the stock price in the short term. Data source: Citeline. The reform measures in the Hong Kong stock market promote liquidity, but risks need to be vigilant.

Stocks ranked among the top in industry market capitalization

Hansoh Pharmaceutical fell 0.95%. According to recent important news:

1. On October 20, Hansoh Pharmaceutical signed a global exclusive licensing agreement for HS-20110 with Roche, receiving an upfront payment of USD 80 million and up to USD 1.45 billion in milestone payments. This agreement improved the company's financial outlook, causing stock price fluctuations. Data source: Haitong International, Huatai Securities

2. On October 20, Nomura Securities raised Hansoh Pharmaceutical's revenue and profit forecasts for 2026, with a slight increase in the target price to HKD 35.5, maintaining a neutral rating. This move reflects the market's recognition of the company's R&D capabilities, leading to stock price fluctuations. Data source: Nomura Securities

3. On October 20, Huatai Securities estimated that Hansoh Pharmaceutical's innovative drug sales revenue would exceed RMB 10 billion in 2025, with the proportion of innovative drug revenue expected to surpass 80%. This expectation boosted market confidence in the company's future growth, affecting stock price fluctuations. Data source: Huatai Securities. The innovative drug market is favored by capital, but volatility risks need to be vigilant